References

Tramer et al, “Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.” BMJ, 2001 Jul 7;323(7303):16-21.
Liu & Powles, “Cannabinoids: Do they have a role in cancer therapy?” Lett Drug Disc Des, 2006; 32: 76-82(7).
Maida et al, “Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring.” J Support Oncol, 2008 Mar;6(3):119-24.
Temel et al, “Early palliative care for patients with metastatic non-small-cell lung cancer.” N Engl J Med, 2010 Aug 19;363(8):733-42.
Liue, Fowler, & Dalgleish, “Cannabis-derived subsatnces in cancer therapy—an emerging anti-inflammatory role for the cannabinoids.” Curr Clin Pharmacol, 2010 Nov;5(4):281-7.
Scott et al, “Enhancing the activity of cannabidiol and other cannabinoids in vitro through modifications to drug combinations and treatment schedules.” Anticancer Res, 2013 Oct;33(10):4373-80.
Reeve et al, “Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials.” J Natl Cancer Inst, 2014 Jul 8; 106(7).
Smith et al, “Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy.” Cochrane Database Syst Rev, 2015 Nov 12;(11):CD009464.
Ferrell et al, “Integration of palliative care into standard oncology care: American Society of Clinical Oncology Clinical Practice Guideline update.” J Clin Oncol, 2017 Jan;35(1):96-112.
Pergam et al, “Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use.” Cancer, 2017 Nov 15;123(22):4488-4497.
Noyes et al., “Analgesic effect of dela-9-tetrahydrocannabinol.” J Clin Pharmacol, 1975 Feb-Mar;15(2-3):139-43.
Facci et al, “Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide.” Proc Natl Acad Sci U S A, 1995 Apr 11;92(8):3376-80.
Richardson, Kilo & Hargreaves, “Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors.” Pain, 1998 Mar;75(1):111-9.
Walker et al, “The neurobiology of cannabinoid analgesia.” Life Sci, 1999;65(6-7):665-73.
Baker et al, “The therapeutic potential of cannabis.” Lancet Neurol, 2003 May;2(5):291-8.
Teunissen et al, “Symptom prevalence in patients with incurable cancer: a systematic review.” J pain Symptom Manage, 2007 Jul;34(1):94-104.
van den Beuken-van Everdingen, “Prevalence of pain in patients with cancer: a systematic review of the past 40 years.” Ann Oncol, 2007 Sep;18(9):1437-49.
Rahn, Makriyannis, & Hohmann, “Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.” Br J Pharmacol, 2007 Nov;152(5):765-77.
Johnson et al, “Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain.” J Pain Symptom Manage, 2010 Feb;39(2):167-79.
Portenoy, “Treatment of cancer pain.” Lancet, 2011 Jun 25;377(9784):2236-47.
Khasabova et al, “CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain.” Behav Pharmacol, 2011 Sep;22(5-6):607-16.
Khassabova et al, “Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy.” J Neurosci, 2012 May 16;32(20):7091-101.
Ward et al, “Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy.” Br J Pharmacol, 2014 Feb;171(3):636-45.
Greco et al, “Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer.” J Clin Oncol, 2014 Dec 20;32(36):4149-54.
Gibson & McConigley, “Unplanned oncology admissions within 14 days of non-surgical discharge: a retrospective study.” Support Care Cancer, 2016 Jan;24(1):311-7.
Wiffen et al, “Opioids for cancer pain – an overview of Cochrane review.” Cochrane Database Syst Rev, 2017 Jul 6;7:CD012592.
Griffin et al, “On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993.” Ann Oncol, 1996 Feb;7(2):189-95.
Tramer et al, “Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.” BMJ, 2001 Jul 7;323(7303):16-21.
Grunberg et al, “Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.” Cancer, 2004 May 15;100(10):2261-8.
Hesketh, “Chemotherapy-induced nausea and vomiting.” N Engl J Med, 2008 Jun 5;358(23):2482-94.
Duran et al, “Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting.” Br J Clin Pharmacol, 2010 Nov;70(5):656-63.
Rock & Parker, “Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping (a model of nausea-induced behavior) in rats.” Br J Pharmacol, 2013 Jun;169(3):685-92.
Rock & Parker, “Suppression of lithium chloride-induced conditioned gaping (a model of nausea-induced behavior) in rats (using the taste reactivity test) with metoclopramide is enhanced by cannabidiolic acid.” Pharmacol Biochem Behav, 2013 Oct;111:84-9.
Escobar et al, “Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study.” Supprt Care Cancer, 2015 Sep;23(9):2833-40.
Smith et al, “Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy.” Cochrane Database Syst Rev, 2015 Nov 12;(11):CD009464.
Rock, Limebeer, & Parker, “Effect of combined doses of Δ(9)-tetrahydrocannabinol (THC) and cannabidiolic acid (CBDA) on acute and anticipatory nausea using rat (Sprague- Dawley) models of conditioned gaping.” Psychopharmacology (Berl), 2015 Dec;232(24):4445-54.
Rock & Parker, “Cannabinoids as potential treatment for chemotherapy-induced nausea and vomiting.” Front Pharmacol, 2016 Jul 26;7:221.
Kuchuk et al, “Patient perceptions about potential side effects and benefits from chemotherapy agents.” J Clin Oncol, 2017.
Dranitsaris et al, “The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting.” Ann Oncol, 2017 Jun 1;28(6):1260-1267.
Hesketh et al, “Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.” J Clin Oncol, 2017 Oct 1;35(28):3240-3261.
Aapro, “CINV: still troubling patients after all these years.” Support Care Cancer, 2018; 26(Suppl 1): 5–9.
Dewys et al, “Prognostic effect of weight loss prior to chemotherapy in cacner patients. Eastern Cooperative Oncology Group.” Am J Med, 1980 Oct;69(4):491-7.
Foltin et al, “Behavioral analysis of marijuana effects on food intake in humans.” Pharmacol Biochem Behav, 1986 Sep;25(3):577-82.
Jatoi et al, “Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study.” J Clin Oncol, 2002 Jan 15;20(2):567-73.
Vicker & Kennett, “Cannabinoids and the regulation of ingestive behavior.” Curr Drug Targets, 2005 Mar;6(2):215-23.
Fride, Bregman, & Kirkham, “Endocannabinoids and food intake: new born suckling and appetite regulation in adulthood.” Exp Biol Med (Maywood), 2005 Apr;230(4):225-34.
Strasser et al, “Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial for the Cannabis-In-Cachexia-Study-Group.” J Clin Oncol, 2006 Jul 20;24(21):3394-400.
Evans et al, “Cachexia: a new definition.” Clin Nutr, 2008 Dec;27(6):793-9.
Capuano et al, “Prevalence and influence of malnutrition on quality of life and performance status in patients with locally advanced head and neck cancer before treatment.” Support Care Cancer, 2010 Apr;18(4):433-7.
Brisboi et al, “Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial.” Ann Oncol, 2011 Sep;22(9):2086-93.
Morishita et al, “Prevalence of sarcopenia and relevance of body composition, physiological function, fatigue, and health-related quality of life in patients before allogenic hematopoietic stem cell transplantation.” Support Care Cancer, 2012 Dec;20(12):3161-8.
Ruiz Garcia et al, “Megestrol acetate for treatment of anorexia-cachexia syndrome.” Cochrane Database Syst Rev, 2013 Mar 28;(3):CD004310.
Oray et al, “Long-term side effects of glucocorticoids.” Expert Opin Drug Saf, 2016;15(4):457-65.
Maida et al, “Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring.” J Support Oncol, 2008 Mar;6(3):119-24.
Brintzenhofe-Szoc et al, “Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type.” Psychosomatics, 2009 Jul-Aug;50(4):383-91.
Waissengrin et al., “Patterns of use of medical cannabis among Israeli cancer patients: a single institution experience.” J Pain Symptom Manage, 2015 Feb;49(2):223-30.
Whiting et al, “Cannabinoids for medical use: a systematic review and meta-analysis.” JAMA, 2015, Jun 23-30;313(24):2456-73.
Birdsall, Birdsall, & Tims, “The use of medical marijuana in cancer.” Curr Oncol Rep, 2016 Jul;18(7):40.
Pitman et al, “Depression and anxiety in patients with cancer.” BMJ, 2018 Apr 24; 361:k1415.
Seibert et al, “Cannabis in cancer patients (CP) to improve quality of life (QOL) and cancer related symptoms (CRS): Illinois Cancer Care cannabis education and clinical analysis.” J Clin Oncol, 2018, 36:15_suppl, e18812-e18812.
Zhang et al, “Association of marijuana use with psychosocial and quality of life outcomes among patients with head and neck cancer.” JAMA Otolaryngol Head Neck Surg, 2018 Nov 1;144(11):1017-1022.